XBiotech Statistics
Total Valuation
XBiotech has a market cap or net worth of $82.01 million. The enterprise value is -$71.54 million.
Important Dates
The next estimated earnings date is Wednesday, November 12, 2025, after market close.
| Earnings Date | Nov 12, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
XBiotech has 30.49 million shares outstanding. The number of shares has increased by 0.08% in one year.
| Current Share Class | 30.49M |
| Shares Outstanding | 30.49M |
| Shares Change (YoY) | +0.08% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 36.43% |
| Owned by Institutions (%) | 11.35% |
| Float | 19.38M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.47 |
| P/TBV Ratio | 0.47 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 40.16
| Current Ratio | 40.16 |
| Quick Ratio | 39.82 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -73.81 |
Financial Efficiency
Return on equity (ROE) is -15.23% and return on invested capital (ROIC) is -12.03%.
| Return on Equity (ROE) | -15.23% |
| Return on Assets (ROA) | -11.59% |
| Return on Invested Capital (ROIC) | -12.03% |
| Return on Capital Employed (ROCE) | -20.90% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$306,120 |
| Employee Count | 92 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, XBiotech has paid $25,000 in taxes.
| Income Tax | 25,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -64.68% in the last 52 weeks. The beta is 0.84, so XBiotech's price volatility has been lower than the market average.
| Beta (5Y) | 0.84 |
| 52-Week Price Change | -64.68% |
| 50-Day Moving Average | 2.98 |
| 200-Day Moving Average | 3.44 |
| Relative Strength Index (RSI) | 30.53 |
| Average Volume (20 Days) | 51,286 |
Short Selling Information
The latest short interest is 165,989, so 0.54% of the outstanding shares have been sold short.
| Short Interest | 165,989 |
| Short Previous Month | 303,572 |
| Short % of Shares Out | 0.54% |
| Short % of Float | 0.86% |
| Short Ratio (days to cover) | 3.71 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -36.54M |
| Pretax Income | -30.44M |
| Net Income | -28.16M |
| EBITDA | -34.78M |
| EBIT | -36.54M |
| Earnings Per Share (EPS) | -$0.92 |
Full Income StatementBalance Sheet
The company has $152.94 million in cash and n/a in debt, giving a net cash position of $152.94 million or $5.02 per share.
| Cash & Cash Equivalents | 152.94M |
| Total Debt | n/a |
| Net Cash | 152.94M |
| Net Cash Per Share | $5.02 |
| Equity (Book Value) | 173.06M |
| Book Value Per Share | 5.68 |
| Working Capital | 151.03M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$25.09 million and capital expenditures -$567,000, giving a free cash flow of -$25.66 million.
| Operating Cash Flow | -25.09M |
| Capital Expenditures | -567,000 |
| Free Cash Flow | -25.66M |
| FCF Per Share | -$0.84 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
